• Assay Selection Tool

BellBrook Labs

  • Products
    • Transcreener® HTS Assay Kits
      • Transcreener® ADP² Kinase Assay Kits
        • Transcreener® ADP2 Assay Kit – FP Readout
        • Transcreener® ADP2 Assay Kit – FI Readout
        • Transcreener® ADP2 Assay Kit – TR-FRET Readout
      • Transcreener® ADO CD73 Assay Kit
      • Transcreener® AMP²/GMP² Phosphodiesterase Assay Kits
        • Transcreener® AMP2/GMP2 FP Assay
        • Transcreener® AMP2/GMP2 Assay Kit – TR-FRET Readout
      • Transcreener® cGAMP cGAS Assay Kits
        • Transcreener® cGAMP Assay Kit – FP Readout
        • Transcreener® cGAMP Assay Kit – TR-FRET Readout
      • Transcreener dAMP Exonuclease Assay Kit
      • Transcreener® EPIGEN SAH Methyltransferase Assay Kit
      • Transcreener® GDP GTPase Assay Kits
        • Transcreener® GDP Assay Kit – FP Readout
        • Transcreener® GDP Assay Kit – FI Readout
        • Transcreener® GDP Assay Kit – TR-FRET Readout
      • Transcreener® UDP² Glycosyltransferase Assay Kits
        • Transcreener® UDP2 Assay Kit – FP Readout
        • Transcreener® UDP2 Assay Kit – FI Readout
        • Transcreener® UDP2 Assay Kit – TR-FRET Readout
      • Transcreener® 2-5A OAS Assay Kit
    • AptaFluor® HTS Assay Kits
      • AptaFluor® SAH Methyltransferase Assay Kit
    • Enzyme Assay Systems
      • TREX1 Assay System
    • Recombinant Enzymes
      • Human cGAS Enzyme
      • Mouse cGAS Enzyme
      • Human DDX3 Enzyme
      • Human OAS1 Enzyme
      • Human TREX1 Enzyme
    • Assay Plates
    • Ordering Information
  • Services
    • Assay Development Services
    • Lead Discovery Services
    • CD38 Assay Services
    • GTPase Profiling Services
  • Assays by Target
    • Kinase Assays
      • ADK Assays – Application
      • AMPK Assays – Application
      • IKK-beta Assays – Application
      • IRAK4 Assays – Application
      • JAK1 Assays – Application
      • JAK3 Assays – Application
      • MAPK8 Assays – Application
      • PKR Assays – Application
      • RIPK1 Assays – Application
      • TBK1 Assays – Application
    • GTPase Assays
      • GAP Assays – Application
      • GEF Assays – Application
      • KRAS Assays – Application
      • HRAS Assays – Application
      • NRAS Assays – Application
      • RRAS Assays – Application
      • Rac1 Assays – Application
      • RhoA Assays – Application
      • RhoC Assays – Application
      • Cdc42 Assays – Application
      • Ran Assays – Application
    • Methyltransferase Assays
      • EZH2 Assays – Application
      • G9a Assays – Application
      • SET7/9 Assays – Application
      • SET8 Assays – Application
      • PRMT1 Assays – Application
      • PRMT3 Assays – Application
      • PRMT4 Assays – Application
    • STING Pathway Assays
      • cGAS Assay Kits
      • ENPP1 Assays – Application
      • TREX1 Assay System
      • IKK-beta Assays – Application
      • TBK1 Assays – Application
    • Nucleotidase Assays
      • CD38 Assay Services
      • CD39 Assays – Application
      • CD73 Activity Assay Kits
    • Helicase / ATPase Assays
      • DDX3 Assays – Application
      • NSP13 Assays – Application
      • P97 Assays – Application
    • Glycosyltransferase Assays
      • Toxin B Assays – Application
      • GALNT2 Assays – Application
      • GALNT3 Assays – Application
      • BGalT1 Assays – Application
    • Phosphodiesterase Assays
      • PDE3 Assays – Application
      • PDE4 Assays – Application
      • PDE5 Assays – Application
      • PDE7 Assays – Application
    • Ligase and Synthetase Assays
      • SUMO E1 Assays – Application
      • Acyl CoA Synthetase Assays – Application
      • S-Acetyl CoA Synthetase Assays – Application
    • Exonuclease Assays
      • TREX1 Assay System
    • OAS Assays
      • OAS1 Assay Kits
    • Other Enzyme Assays
      • NUDT5 Assays – Application
  • Resources
    • Technical Manuals
    • Transcreener® Assays – Instrument Compatibility
    • Application Notes
    • Posters and Presentations
    • Publications
    • Transcreener® FAQ’s
    • Guides
      • Residence Time Guide
      • Hit Prioritization Guide
      • Kinases in Innate Immunity
  • Company
    • President’s Message
    • International Distributors
    • Careers
    • Downloads
    • Contact Us
  • Blog
  • MY CART
    No products in cart.

Finding Inhibitors for a Cancer Target: CDK12 Activity Assays Accelerate the Search

by Bellbrook Labs / Tuesday, 03 December 2019 / Published in Emerging Targets, HTS Assays
CDK12 Activity Assays Find Inhibitors Cancer Treatment

All systems within our bodies function by means of proteins. When these proteins aren’t made correctly, our body malfunctions.  The short explanation: DNA is at the fabric of forming a functional protein; genes (made of DNA) get transcribed and then translated to become proteins. During this complex process, genes are not always correctly transcribed and the correct, working protein isn’t made. And, this is where cancer enters the story. Cancer is messy! There are numerous genes involved and multiple ways they can become mutated or silenced, leading to cancer.

It makes sense, that most of the mutated genes that contribute to cancer are involved in DNA replication, transcription, and gene expression. Cyclin-dependent kinases (CDK) are a family of serine/threonine protein kinases that regulate transcriptional and posttranscriptional processes. As transcription plays an important role in ensuring healthy individuals, certainly these proteins have the same objective.

Responsibility of CDK12 and Relationship to Cancer

As mentioned, genes have several opportunities to acquire mutations; consequently, our bodies have a DNA damage repair (DDR) system to prevent these threats. Studies have shown that CDK12 maintains genomic stability and expression of DDR genes.1   Furthermore, tumors arise when aberrations in CDK12 are present.1   Interestingly, microarray analysis shows that the deletion of CDK12 affect several genes including a decrease in BRCA1.1

Aiding in a stable genome isn’t the only task of CDK12 as research has shown its involvement in development, transcription regulation, and splicing as well.2 Even more exceptional, CDK12 appears to have both tumor-suppressive and tumorigenic properties according to research.2 Nonetheless, studies have found that CDK12 inhibitors have decreased tumor growth and scientists want to continue finding similar solutions.2

CDK12 Activity Assays  

Although the protein kinase has many responsibilities, there is still much to learn regarding specific details into the exact functions and how alterations end in cancer. Measuring the activity of CDK12 is necessary when performing general research and for finding therapeutic strategies to fight against cancer in the case of CDK12 inhibitors.  Briefly, the nature of a protein kinase is to assist in the transfer of a phosphate from ATP to another molecule (or substrate), forming ADP as a product that can be measured by using specific antibody labeled with a fluorophore. A change in signal can then be used to measure enzymatic activity, screen for inhibitors, and perform SAR.

References

  1. Lui GYL, Grandori C, Kemp CJ. CDK12: an emerging therapeutic target for cancer. J Clin Pathol. 2018;71(11):957-962. doi:10.1136/jclinpath-2018-205356
  2. Paculová H, Kohoutek J. The emerging roles of CDK12 in tumorigenesis. Cell Div. 2017;12(1). doi:10.1186/s13008-017-0033-x
Tagged under: CDK12 Activity Assays, kinase assay, Transcreener ADP Kinase Assay

What you can read next

HSP90 Inhibitor Immunotherapy
Enhancing Checkpoint Blockade Immunotherapy: Sensitizing Tumors with HSP90 Inhibitors
SIRT6: Keeping Tumor Cells in Check
BellBrook Labs Launches HTS Assay Platform for Targeting GPCR Regulatory Proteins

Categories

  • Company
  • Emerging Targets
  • Epigenetics
  • HTS Assays
  • Innate Immunity
  • Neurodegenerative Diseases
  • News
  • Products
  • Resources
  • Success Stories
  • Uncategorized

Recent Posts

  • SLAS 2023 Conference Exhibitor Announcement

    SLAS 2023 – HTS Assays and Discovery Services

    BellBrook Labs will exhibit and present posters...
  • BTK's Involved in Systemic lupus erythematosus

    The Challenging Search for BTK Inhibitors

    Bruton’s Tyrosine Kinase (BTK) is a 76kDa...
  • SARM1 Causes Axonal Death

    SARM1 Forefronts Research into Major Neurological Diseases

    SARM1 [Sterile alpha & toll/interleukin rec...
  • SIRT2 Affects Neurodegenerative Diseases

    SIRT2 Isoforms in Neurodegenerative Diseases & Cancer

    Silent information regulator type 2 (Sirtuin 2 ...
  • Patient With WRN Helicase Syndrome

    Can WRN Helicase Inhibitors Treat MSI-H Cancers?

    Over 100 years ago, Otto Werner first character...

Archives

BellBrook Labs
5500 Nobel Drive, Suite 230
Madison, Wisconsin 53711 USA
(608) 443-2400

info@bellbrooklabs.com

 Copyright © 2022 BellBrook Labs | All Rights Reserved | Privacy Policy | Terms of Use | FCOI | Sitemap

TOP